AngioGenex (AGGX) 10-Q 13 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 09, 2018
FIXED ASSETS [Abstract]
Entity Registrant Name	ANGIOGENEX, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		29,386,667
Amendment Flag	false
Entity Central Index Key	1,085,596
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash	$ 117,341	$ 493,676
Prepaid expenses	31,245	21,634
TOTAL CURRENT ASSETS	148,586	515,310
TOTAL ASSETS	148,586	515,310
CURRENT LIABILITIES
Accounts payable and accrued expenses	459,760	383,695
Accounts payable and accrued expenses - related parties	402,537	495,536
Notes payable	1,000	11,000
Notes payable - related parties	127,750	127,750
Accrued interest	45,052	51,081
Accrued interest - related parties	78,458	73,321
TOTAL CURRENT LIABILITIES	1,114,557	1,142,383
LONG-TERM LIABILITIES
Notes payable, related parties	27,450	27,450
STOCKHOLDERS' DEFICIT
Preferred stock, 5,000,000 shares authorized, $0.001 par value, no shares issued and outstanding	0	0
Common stock, 150,000,000 shares authorized, $0.001 par value, shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	29,387	29,387
Additional paid-in capital	5,903,242	5,892,359
Accumulated deficit	(6,926,050)	(6,576,269)
TOTAL STOCKHOLDERS' DEFICIT	(993,421)	(654,523)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 148,586	$ 515,310

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred Stock
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in Shares)	5,000,000	5,000,000
Preferred stock, shares issued (in Shares)	0	0
Preferred stock, shares outstanding (in Shares)	0	0
Common Stock
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in Shares)	150,000,000	150,000,000
Common stock, shares issued (in Shares)	29,386,667	29,386,667
Common stock, shares outstanding (in Shares)	29,386,667	29,386,667

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
EXPENSES
Research and development	$ (1,291)	$ 17,997	$ 10,975	$ 252,923
General and administrative	79,621	99,980	332,101	357,890
TOTAL OPERATING EXPENSES	78,330	117,977	343,076	610,813
LOSS FROM OPERATIONS	(78,330)	(117,977)	(343,076)	(610,813)
OTHER EXPENSE
Other income (expense)	29	(207)	206	(662)
Interest Income	138	92	653	92
Interest expense, net	(2,468)	(3,019)	(7,564)	(8,386)
TOTAL OTHER EXPENSE	(2,301)	(3,134)	(6,705)	(8,956)
LOSS BEFORE INCOME TAXES	(80,631)	(121,111)	(349,781)	(619,769)
INCOME TAXES	0	0	0	0
NET LOSS	$ (80,631)	$ (121,111)	$ (349,781)	$ (619,769)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED	$ 0	$ 0	$ (.01)	$ (.02)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK SHARES OUTSTANDING - BASIC AND DILUTED	29,386,667	28,878,624	29,386,667	27,213,187

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Shares Issuable	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2016	$ 25,367	$ 5,116,065	$ 1,000	$ (5,893,240)	$ (750,808)
Beginning Balance, Shares at Dec. 31, 2016	25,366,667
Sale of common stock, shares	1,000,000
Sale of common stock, value	$ 1,000	0	(1,000)	0	0
Stock-based compensation	0	25,316	0	0	25,316
Net Loss	0	0	0	(89,787)	(89,787)
Ending Balance, Amount at Mar. 31, 2017	$ 26,367	5,141,381	0	(5,983,027)	(815,279)
Ending Balance, Shares at Mar. 31, 2017	26,366,667
Beginning Balance, Amount at Dec. 31, 2016	$ 25,367	5,116,065	1,000	(5,893,240)	(750,808)
Beginning Balance, Shares at Dec. 31, 2016	25,366,667
Net Loss					(619,769)
Ending Balance, Amount at Sep. 30, 2017	$ 26,367	5,875,790	3,020	(6,513,009)	(607,832)
Ending Balance, Shares at Sep. 30, 2017	26,366,667
Beginning Balance, Amount at Dec. 31, 2016	$ 25,367	5,116,065	1,000	(5,893,240)	$ (750,808)
Beginning Balance, Shares at Dec. 31, 2016	25,366,667
Issuance of common stock for services,shares					3,200
Net Loss					$ (619,769)
Ending Balance, Amount at Dec. 31, 2017	$ 29,387	5,892,359	0	(6,576,269)	(654,523)
Ending Balance, Shares at Dec. 31, 2017	29,386,667
Beginning Balance, Amount at Mar. 31, 2017	$ 26,367	5,141,381	0	(5,983,027)	(815,279)
Beginning Balance, Shares at Mar. 31, 2017	26,366,667
Stock-based compensation	$ 0	60,558	0	0	60,558
Net Loss	0	0	0	(408,871)	(408,871)
Ending Balance, Amount at Jun. 30, 2017	$ 26,367	5,201,939	0	(6,391,898)	(1,163,592)
Ending Balance, Shares at Jun. 30, 2017	26,366,667
Sale of common stock, shares	0
Sale of common stock, value	$ 0	747,000	3,000	0	750,000
Issuance of common stock for services,shares	0
Issuance of common stock for services, amount	$ 0	3,180	20	0	3,200
Stock-based compensation	0	(76,329)	0	0	(76,329)
Net Loss	0	0	0	(121,111)	(121,111)
Ending Balance, Amount at Sep. 30, 2017	$ 26,367	5,875,790	3,020	(6,513,009)	(607,832)
Ending Balance, Shares at Sep. 30, 2017	26,366,667
Beginning Balance, Amount at Dec. 31, 2017	$ 29,387	5,892,359	0	(6,576,269)	(654,523)
Beginning Balance, Shares at Dec. 31, 2017	29,386,667
Stock-based compensation	$ 0	(10,530)	0	0	(10,530)
Net Loss				(180,941)	(180,941)
Ending Balance, Amount at Mar. 31, 2018	$ 29,387	5,881,829	0	(6,757,210)	(845,994)
Ending Balance, Shares at Mar. 31, 2018	29,386,667
Beginning Balance, Amount at Dec. 31, 2017	$ 29,387	5,892,359	0	(6,576,269)	$ (654,523)
Beginning Balance, Shares at Dec. 31, 2017	29,386,667
Issuance of common stock for services,shares					0
Net Loss					$ (349,781)
Ending Balance, Amount at Sep. 30, 2018	$ 29,387	5,903,242	0	(6,926,050)	(993,421)
Ending Balance, Shares at Sep. 30, 2018	29,386,667
Beginning Balance, Amount at Mar. 31, 2018	$ 29,387	5,881,829	0	(6,757,210)	(845,994)
Beginning Balance, Shares at Mar. 31, 2018	29,386,667
Stock-based compensation	$ 0	18,562	0	0	18,562
Net Loss				(88,209)	(88,209)
Ending Balance, Amount at Jun. 30, 2018	$ 29,387	5,900,391	0	(6,845,419)	(915,641)
Ending Balance, Shares at Jun. 30, 2018	29,386,667
Stock-based compensation	$ 0	2,851	0	0	2,851
Net Loss				(80,631)	(80,631)
Ending Balance, Amount at Sep. 30, 2018	$ 29,387	$ 5,903,242	$ 0	$ (6,926,050)	$ (993,421)
Ending Balance, Shares at Sep. 30, 2018	29,386,667

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (349,781)	$ (619,769)
Adjustments to reconcile net loss to net cash used in operations:
Stock-based compensation issuance of common stock options	$ 10,883	$ 9,545
Issuance of common stock for services rendered - related party	0	3,200
Changes in operating assets and liabilities:
Prepaid expenses	$ 19,444	$ (30,600)
Decrease in accrued expenses	52,126	131,967
Increase/(decrease) in accrued expenses - related party	(92,999)	102,326
Increase in accrued interest	(6,029)	1,899
Increase in accrued interest - related parties	5,137	4,090
Net cash used by operating activities	(361,219)	(397,342)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of notes payable	(10,000)	0
Repayment of financed insurance premiums	(5,116)	0
Proceeds from common stock subscription	0	750,000
Net cash (used in) provided by financing activities	(15,116)	750,000
Net (decrease) increase in cash	(376,335)	352,658
Cash, beginning of period	493,676	272,471
Cash, end of period	117,341	493,676
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest and income taxes: Interest expense	8,371	2,397
Cash paid for interest and income taxes: Income taxes	0	0
SUPPLEMENTAL NON-CASH FINANCING ACTIVITY:
Insurance premiums financed by a note	$ 29,055	$ 0

NOTE 1 - ORGANIZATION AND DESCR

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS The condensed consolidated financial statements include AngioGenex, Inc. (“AngioGenex” or the “Company”) and its wholly owned subsidiary AngioGenex Therapeutics, Inc. AngioGenex was incorporated in the State of New York on March 31, 1999. AngioGenex is a bio-pharmaceutical company dedicated to the development and commercialization of a novel, inexpensive treatment for vascular diseases including many forms of cancer, and macular degeneration.

NOTE 2 - LIQUIDITY AND BASIS OF

NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2018
Note 2 - Liquidity And Basis Of Presentation
NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION	NOTE 2 – LIQUIDITY AND BASIS OF PRESENTATION The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has incurred substantial net losses since inception. The future of the Company is dependent upon obtaining additional financing and generating revenue to fund research and development activities and to support operations. However, there is no assurance that the Company will be able to obtain additional financing. Furthermore, there is no assurance that the United Stated Food and Drug Administration (the “FDA”) will grant future approval of the Company’s prospective products or that profitable operations can be attained as a result thereof. Our financial statements do not include any recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the Company cannot continue as a going concern. The Company anticipates that its principal source of funds for the next year will be the issuance of additional equity or debt instruments for cash. Management plans to seek additional capital from new equity securities issuances that will provide funds needed to increase liquidity, fund internal growth and fully implement its business plan. Based on the Company's current cash usage expectations, management believes it will not have sufficient liquidity to fund its operations through December 2018. Further, management cannot provide any assurance that it is probable that the Company will be successful in accomplishing any of its plans to raise debt or equity financing. Collectively, these factors raise substantial doubt regarding the Company's ability to continue as a going concern.

NOTE 3 - BASIS OF REPORTING AND

NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES The accompanying condensed consolidated financial statements reflect the accounts of the Company and its wholly-owned subsidiary and have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany balances and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, these interim unaudited condensed consolidated financial statements contain all of the adjustments of a normal and recurring nature which are considered necessary for a fair presentation of the financial position of the Company and the results of its operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the operating results for the entire year. The accompanying Condensed Consolidated Balance Sheets at December 31, 2017, were derived from audited annual financial statements but do not contain all of the footnote disclosures from the annual financial statements. These financial statements should be read in conjunction with the annual financial statements and related disclosures included in the audited financial statements for the year ended December 31, 2017. The accompanying interim unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes. As of September 30, 2018, the Company’s significant accounting policies and estimates remain unchanged from those detailed in the audited financial statements for the year ended December 31, 2017. Recent Accounting Pronouncements Not Yet Adopted The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). ASUs not discussed below were considered by management and either determined to be not applicable or expected to have minimal impact on our consolidated balance sheets or statements of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on the Company's financial position or results of operations, as the Company has not entered into any lease agreements. In June 2018, FASB issued ASU No. 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of Accounting Standards Codification, or ASC, 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We are currently evaluating the effect of this guidance on our consolidated financial statements and disclosures.

NOTE 4 - AGREEMENT WITH MEMORIA

NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER (“MSKCC”)	9 Months Ended
	Sep. 30, 2018
Note 4 - Agreement With Memorial Sloan Kettering Cancer Center
NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER ("MSKCC")	NOTE 4 – AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER (“MSKCC”) In March 2000, in exchange for $30,000, the Company obtained from MSKCC, a related party, an exclusive worldwide right and license in the field of use, including to make, have made, use, lease, commercialize and sell licensed products and to use licensed processes derived from the invention of our two leading drug candidates. In 2014, the Company issued 810,000 shares of common stock in exchange for previously agreed milestone, royalty and sub-license payments. The aforementioned issuance of shares of common stock released the Company from any future obligations and there are no remaining obligations under the agreement. In July 2017 the Company executed a service agreement with MSKCC, a related party, to provide pre-clinical research services in connection with the development and Investigational New Drug (IND) Application for the Company’s lead compound and its derivatives. The effective date of the agreement is February 2, 2017, and $250,000 of fees and costs have been incurred as of September 30, 2018.

NOTE 5 - RELATED PARTY TRANSACT

NOTE 5 - RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2018
Finite-Lived Intangible Assets, Net [Abstract]
NOTE 5 - RELATED PARTY TRANSACTIONS	NOTE 5 – RELATED PARTY TRANSACTIONS The Company owes MSKCC for research and development expenses $25,000 and $100,000 as of September 30, 2018 and 2017, respectively. An officer of the Company allows the Company to use space in his offices for file keeping and other business purposes. The Company pays no rent for this space. This same officer also provides services to the Company in the form of accounting, bookkeeping and tax preparation, for which the Company is billed. As of September 30, 2018 and 2017, the Company owed the officer’s business $145,376 and $153,315, respectively, which is included in accounts payable and accrued expenses – related parties in our financial statements. At September 30, 2018 and 2017, the Company owed a former officer $95,000 for unpaid salary pursuant to an agreement. In addition, two former officers are owed $99,159 for unreimbursed business expenses as of September 30, 2018 and 2017, respectively, which is included in accounts payable and accrued expenses - related parties in our financial statements. Two shareholders provided legal services to the Company, for which the Company is billed. As of September 30, 2018 and 2017, the Company owed these shareholders $38,002, which is included in accounts payable and accrued expenses – related parties in the financial statements.

NOTE 6 - FINANCED INSURANCE PRE

NOTE 6 - FINANCED INSURANCE PREMIUMS	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
NOTE 6 - FINANCED INSURANCE PREMIUMS	NOTE 6 – FINANCED INSURANCE PREMIUMS In August 2018, the Company entered into an agreement to finance $29,055 of its insurance premiums. The agreement provides for monthly repayments of principal and interest accrued at 8.54% per annum, commencing on September 10, 2018. At September 30, 2018 the balance was $23,939 and has been included with accounts payable and accrued expenses in the financial statements.

NOTE 7 - NOTES PAYABLE

NOTE 7 - NOTES PAYABLE	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
NOTE 7 - NOTES PAYABLE	NOTE 7 – NOTES PAYABLE At September 30, 2018, the Company’s loans from related parties total $155,200 of principal and accrued interest of $78,458. The interest rate on these notes vary from 0% to 6%. Related parties include directors, officers, stockholders and stock option holders. At September 30, 2018, the Company’s loans from unrelated parties total $1,000 in principal and $771 of accrued interest. The interest rate on these notes is 6%, and the principal and accrued interest is due on demand. On November 19, 2007, the Company obtained an unsecured loan in the amount of $10,000 from an unrelated party. The loan was repaid on April 6, 2018. The Company paid interest payments of $6,171 on March 5, 2018 and $61 on April 6, 2018, totaling $6,232 of interest accrued and paid on this loan. The principal maturity on all of these notes payable (including related parties and non-related parties) is as follows: September 30, 2019 $ 128,750 September 30, 2020 4,700 September 30, 2021 - September 30, 2022 - Thereafter 22,750 $ 156,200

NOTE 8 - CAPITAL STOCK

NOTE 8 - CAPITAL STOCK	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
NOTE 8 - CAPITAL STOCK	NOTE 8 – CAPITAL STOCK Common Stock The Company is authorized to issue 150,000,000 shares of $0.001 par value common stock. In July 2017, the Company sold 3,000,000 shares of common stock to related parties at $0.25 per share for proceeds of $750,000.

NOTE 9 - STOCK OPTIONS

NOTE 9 - STOCK OPTIONS	9 Months Ended
	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
NOTE 9 - STOCK OPTIONS	NOTE 9 – STOCK OPTIONS The Company did not grant any options during the nine months ended September 30, 2018. As of September 30, 2018, 3,890,000 options are available under the stock option plan approved by the board of directors and the stockholders of the Company on September 27, 2012 (the “2012 Plan”). The following table summarizes information regarding outstanding stock option grants as of September 30, 2018: Outstanding Exercisable Range of Exercise Prices Granted Stock Options Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Granted Stock Options Exercisable Weighted- Average Exercise Price $ 0.01-0.05 6,659,999 2.10 $ 0.04 6,659,999 $ 0.04 0.08-0.10 3,570,000 2.63 0.08 3,220,000 0.08 0.17 1,560,000 1.05 0.17 1,560,000 0.17 $ 0.01-0.17 11,789,999 2.12 $ 0.07 11,439,999 $ 0.07 Compensation expense of $2,851 and $(76,329) has been recognized for stock options for the three months ended September 30, 2018 and 2017, and $10,883 and $9,545 has been recognized for stock options for the nine months ended September 30, 2018 and 2017, respectively. The aggregate intrinsic value of the outstanding and exercisable options at September 30, 2018 was $2,134,300 and $2,074,800 respectively. At September 30, 2018, $17,010 of unamortized compensation expense for unvested options is expected to be recognized over the next year. During 2016, the Company granted 200,000 stock options to a consultant, 100,000 of which will vest upon obtaining certain regulatory approval and submission of an IND application to the FDA, and 100,000 of which will vest upon the commencement of the Phase I human clinical trial. The first 100,000 stock options described above are accounted for as variable performance based option awards, as the performance is probable of occurring, and will be adjusted each reporting period to reflect the estimated fair value until such approvals and filings are obtained. The second 100,000 stock options are contingent upon an event (initiation of a clinical trial) in the future, and management cannot determine if this event is probable at this time. The fair value of these options as of September 30, 2018 and 2017 was $18,341 and $24,933, respectively. The change in value of $14,650 and ($15,988) has been included with stock based compensation in research and development for the nine months ended September 30, 2018 and 2017, respectively.

NOTE 10 - COMMITMENTS AND CONTI

NOTE 10 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
NOTE 10 - COMMITMENTS AND CONTINGENCIES	NOTE 10 — COMMITMENTS AND CONTINGENCIES In July 2006, Comparative Biosciences Inc. (“CompBio”) , a company that AngioGenex hired to breed and house a colony of its proprietary “Id-Knockout” mice, sued the Company claiming approximately $200,000 in unpaid invoices. AngioGenex’s response included counter-claims for CompBio’s breaches of contract, as well as a number of business torts. On November 6, 2007, the parties agreed to a disposition of the suit under a stipulated judgment and settlement agreement pursuant to which: CompBio must return the laboratory mice and all scientific data from the research, CompBio agreed to forego all intellectual property rights in the mice and in the research that it acknowledged belong to AngioGenex, and AngioGenex agreed to pay CompBio $55,000 in installments over a 5-year period, plus accumulated interest at 5% per annum. The stipulated judgment and settlement agreement was filed with the court in November 2007. The Company has not made the required payments since the fourth quarter of 2008, and is in default of this settlement agreement. Under the terms of the agreement, upon receipt of written notification of default from CompBio the Company has five days to cure. Failure by the Company to cure the default results in an increase in the settlement amount to $75,000 plus retroactive interest of 5% on the balance. The Company has not received any notification of default from CompBio as of report date. In November 2007 and various dates in 2008, the Company has made $17,500 payments to CompBio pursuant to the settlement agreement, and had accrued interest of $44,281. Since those dates, no payments have been made.

NOTE 11 - NET LOSS PER SHARE

NOTE 11 - NET LOSS PER SHARE	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
NOTE 11 - NET LOSS PER SHARE	NOTE 11 — NET LOSS PER SHARE Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and issuable during the periods presented. The computation of diluted loss per share is similar to the computation of basic loss per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. The Company has 11,789,999 and 12,289,999 common stock options outstanding as of September 30, 2018 and 2017, respectively. These options are excluded from the calculation as they are antidilutive.

NOTE 3 - BASIS OF REPORTING A_2

NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Not Yet Adopted The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). ASUs not discussed below were considered by management and either determined to be not applicable or expected to have minimal impact on our consolidated balance sheets or statements of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on the Company's financial position or results of operations, as the Company has not entered into any lease agreements. In June 2018, FASB issued ASU No. 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of Accounting Standards Codification, or ASC, 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We are currently evaluating the effect of this guidance on our consolidated financial statements and disclosures.

NOTE 7 - NOTES PAYABLE (Tables)

NOTE 7 - NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Principle maturity on notes payable	September 30, 2019 $ 128,750 September 30, 2020 4,700 September 30, 2021 - September 30, 2022 - Thereafter 22,750 $ 156,200

NOTE 9 - STOCK OPTIONS (Tables)

NOTE 9 - STOCK OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding stock option grants	Outstanding Exercisable Range of Exercise Prices Granted Stock Options Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Granted Stock Options Exercisable Weighted- Average Exercise Price $ 0.01-0.05 6,659,999 2.10 $ 0.04 6,659,999 $ 0.04 0.08-0.10 3,570,000 2.63 0.08 3,220,000 0.08 0.17 1,560,000 1.05 0.17 1,560,000 0.17 $ 0.01-0.17 11,789,999 2.12 $ 0.07 11,439,999 $ 0.07

NOTE 2 - LIQUIDITY AND BASIS _2

NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Note 2 - Liquidity And Basis Of Presentation
Net loss	$ (80,631)	$ (88,209)	$ (180,941)	$ (121,111)	$ (408,871)	$ (89,787)	$ (349,781)	$ (619,769)	$ (619,769)
Accumulated deficit	$ (6,926,050)						$ (6,926,050)		$ (6,576,269)

NOTE 3 - SUMMARY OF SIGNIFICANT

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
	Sep. 30, 2017USD ($)
Accounting Policies [Abstract]
Stock issued for services, value	$ 3,200

NOTE 4 - AGREEMENT WITH MEMOR_2

NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER (“MSKCC”) (Details) - USD ($)	1 Months Ended	12 Months Ended	20 Months Ended
	Mar. 31, 2000	Dec. 31, 2014	Sep. 30, 2018
Note 4 - Agreement With Memorial Sloan Kettering Cancer Center
MSKCC right and license fee	$ 30,000
MSKCC service agreement fees and costs			$ 250,000
Shares of common stock issued to MSKCC in exchange for previously agreed milestone, royalty and sub-license payments		810,000

NOTE 5 - RELATED PARTY TRANSA_2

NOTE 5 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Finite-Lived Intangible Assets, Net [Abstract]
Owed to MSKCC for research and development expenses	$ 25,000	$ 100,000
Owed to related party business	145,376	153,315
Unpaid salary owed to former officer	95,000	95,000
Owed reimbursed business expenses	99,159	99,159
Legal service fees owed to related party	$ 38,002	$ 38,002

NOTE 6 - FINANCED INSURANCE P_2

NOTE 6 - FINANCED INSURANCE PREMIUMS (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Aug. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Amount of insurance premium financed	$ 29,055	$ 29,055	$ 0
Rate of insurance interest accrued per annum	8.54%
Balance due on Insurance premium		$ 23,939

NOTE 7 - NOTES PAYABLE - PRINCI

NOTE 7 - NOTES PAYABLE - PRINCIPLE MATURITY ON NOTES PAYABLE (Details) - USD ($)	60 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Debt Disclosure [Abstract]
Principle maturity	$ 22,750	$ 0	$ 0	$ 4,700	$ 128,750
Principle maturity total	$ 156,200

NOTE 7 - NOTES PAYABLE (Details

NOTE 7 - NOTES PAYABLE (Details Narrative)	Sep. 30, 2018USD ($)
Debt Disclosure [Abstract]
Loans from related parties- principle	$ 155,200
Loans from related parties- interest	$ 78,458
Max interest rate on related party loans	6.00%
Min interest rate on related party loans	0.00%
Unrelated Party Note total	$ 1,000
Interest accrued on unrelated party advance	$ 771
Interest rate on unrelated party advance	6.00%

NOTE 8 - CAPITAL STOCK (Details

NOTE 8 - CAPITAL STOCK (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Jul. 31, 2017	Sep. 30, 2018	Dec. 31, 2017
Equity [Abstract]
Common stock, Authorized		150,000,000	150,000,000
Shares issued for cash, duration	3,000,000
Price per share, duration	$ .025
Cash paid for shares, duration	$ 750,000	$ 0	$ 750,000

NOTE 9 - STOCK OPTIONS (Details

NOTE 9 - STOCK OPTIONS (Details) - $ / shares	Sep. 30, 2018	Sep. 30, 2017
Stock Options - Number Outstanding	11,789,999	12,289,999
Exercise Price $0.01-0.05
Stock Options - Number Outstanding	6,659,999
Stock Options Outstanding - Average Remaining Contractual Life (in years)	2 years 1 month
Stock Options Outstanding - Weighted Average Exercise Price	$ .04
Stock Options - Number Exercisable	6,659,999
Stock Options Exercisable - Weighted Average Exercise Price	$ 0.04
Exercise Price $0.08-0.10
Stock Options - Number Outstanding	3,570,000
Stock Options Outstanding - Average Remaining Contractual Life (in years)	2 years 7 months
Stock Options Outstanding - Weighted Average Exercise Price	$ .08
Stock Options - Number Exercisable	3,220,000
Stock Options Exercisable - Weighted Average Exercise Price	$ 0.08
Exercise Price $0.17
Stock Options - Number Outstanding	1,560,000
Stock Options Outstanding - Average Remaining Contractual Life (in years)	1 year 1 month
Stock Options Outstanding - Weighted Average Exercise Price	$ .17
Stock Options - Number Exercisable	1,560,000
Stock Options Exercisable - Weighted Average Exercise Price	$ 0.17
Exercise Price $0.01-0.17
Stock Options - Number Outstanding	11,789,999
Stock Options Outstanding - Average Remaining Contractual Life (in years)	2 years 1 month
Stock Options Outstanding - Weighted Average Exercise Price	$ .17
Stock Options - Number Exercisable	11,439,999
Stock Options Exercisable - Weighted Average Exercise Price	$ 0.17

NOTE 9 - STOCK OPTIONS (Detai_2

NOTE 9 - STOCK OPTIONS (Details Narrative)	9 Months Ended
	Sep. 30, 2018shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock Options Granted	0
Stock Options Available	3,890,000

NOTE 10 - COMMITMENTS AND CON_2

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	131 Months Ended
	Sep. 30, 2018	Nov. 06, 2007
Commitments and Contingencies Disclosure [Abstract]
Settlement Agreement amount owed		$ 55,000
Interest rate on settlement agreement, per annum	5.00%
Settlement Agreement payments made	$ 17,500
Settlement Agreement accrued interest	$ 44,281

NOTE 11 - NET LOSS PER SHARE (D

NOTE 11 - NET LOSS PER SHARE (Details Narrative) - shares	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Stock Options - Number Outstanding	11,789,999	12,289,999